| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Research Abstract |
Obesity is known as a major risk factor for the development ofmetabolic syndrome. Recent research suggested that “leptin resistance” is one of the mechanisms responsible for the development of obesity. Therefore, the drug attenuating “leptin resistance” would be promising therapeutic drug target for obesity and metabolic syndrome. In the previous study, we found that endoplasmic reticulum (ER) stresswould be involved in the development of “leptin resistance”. Our purpose of the presentstudy was to find out the mechanism of “leptin resistance” and develop novel drug forthe disease targeting ER stress. In the present study, we analyzed physiological factor, which is responsible for activating ER stress. Furthermore, we investigated the mechanism of the activation of ER stress and pharmacological property of the drug targetingER stress, which could attenuate “leptin resistance”.
|
